Sugi Predict

Sugi Predict / Compounds / SCHEMBL3714513

SCHEMBL3714513

SCHEMBL3714513

Cc1nn2cccnc2c1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 2/20 0.51
▸ PDE2A O00408 1/20 0.49
▸ APOBEC3A P31941 2/20 0.45
▸ APOBEC3G Q9HC16 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.40
▸ HTR6 P50406 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ PIM1 P11309 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ POLB P06746 3/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20669696 0.87 PIK3CG (0.51) PIK3CGPDE2AAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL22102607 0.85 NTRK1 (0.51) PIK3CGPDE2AAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL29773929 0.85 PIK3CG (0.50) PIK3CGPDE2AAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL26172231 0.81 HTR6 (0.53) PIK3CGPDE2AAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL18675323 0.80 PDE2A (0.53) PIK3CGPDE2AALDH1A1NPC1RAB9A
SCHEMBL23728529 0.80 APOBEC3A (0.45) PIK3CGPDE2AAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL16619547 0.80 PIK3CG (0.45) PIK3CGAPOBEC3AAPOBEC3G
SCHEMBL31211823 0.80 SMPD3 (0.46) PIK3CGPDE2AAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL23728636 0.80 PDE2A (0.44) PIK3CGPDE2AAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL18208430 0.79 PIK3CG (0.44) PIK3CGAPOBEC3AAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 — — EP claimed
WO-2015150887-A1 PROCESS FOR THE PREPARATION OF ANAGLIPTIN OR ITS SALTS WOCKHARDT LIMITED (IN) 2015-10-08 — — WO claimed
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 — — EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 — — US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 — — CN disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 — — CN disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 — — US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 — — US disclosed
US-8940742-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2015-01-27 — — US disclosed
US-8940742-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2015-01-27 — — US disclosed
WO-2013154878-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. (US) 2013-10-17 — — WO disclosed
US-20130267521-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE LLC (US) 2013-10-10 — — US disclosed
US-20130267521-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE LLC (US) 2013-10-10 — — US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 — — US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 — — EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 — — WO disclosed
WO-2008157273-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PIK3CG 954/4885PDE2A 528/4885APOBEC3A 4451/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH PIK3CG 1916/4885PDE2A 793/4885APOBEC3A 3536/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP PIK3CG 954/4885PDE2A 528/4885APOBEC3A 4451/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 PIK3CG 18/4885PDE2A 2523/4885APOBEC3A 4598/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PIK3CG 954/4885PDE2A 528/4885APOBEC3A 4451/4885
US-20130267521-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB PIK3CG 7/4885PDE2A 598/4885APOBEC3A 3801/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP PIK3CG 684/4885PDE2A 360/4885APOBEC3A 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.